Menu
Recruiting NCT06797154

A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Subacute Stroke Survivors

No phase Interventional Stroke Stroke Sequelae Hemiparesis;Poststroke/CVA

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: StrokeWear Behavioral Intervention, Usual Care + Sham.
Who it may be relevant to
Registry conditions: Stroke, Stroke Sequelae, Hemiparesis;Poststroke/CVA. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Novel Wrist Wearable Sensor System to Promote Hemiparetic Upper Extremity Use in Home Daily Life of Subacute Stroke Survivors

Overview

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Detailed description

The proposed study is a two-arm randomized clinical trial designed to assess the effects of the StrokeWear system on clinical outcomes over a period of 6-months in subacute stroke survivors. The Intervention group will use StrokeWear system in combination to a motor and behavioral home intervention whereas the Control group will follow usual care which consists of a home-exercise plan (HEP).

Study participants will be asked to take part in 4 evaluation study visits: one screening and enrollment visit, and three evaluation visits (at baseline, at 3 months and at 6 months - at the intervention completion). Subject upper-extremity motor function will be assessed across domains of the International Classification of Functioning, Disability and Health (ICF) model. Groups will be stratified by baseline motor impairment and stroke chronicity.

Subjects randomized to the intervention group will take part of weekly coaching sessions during the first month, bi-weekly sessions during the months 2 and 3, and monthly sessions during months 4-6. These sessions will be held in-person or remotely, based on the study participant preference.

Subjects randomized to the control group will take part of monthly visits, held in-person or remotely (based on study participant preference), to re-evaluate the home-exercise plan and prescribe an update list of exercises for the following month.

Interventions

  • Behavioral StrokeWear Behavioral Intervention
    Behavioral strategies will be incorporated into the Strokewear system to encourage feedback on behavior, goal setting, daily activity action planning (DAAP), and an empowerment/ self management model to foster planned hemiparetic UE use during daily activities in the home and community. Patient empowerment in this study will occur over 6-months as patients gain the ability to use the StrokeWear technology independently and develop skills to self- manage their GDM and DAAP.
  • Other Usual Care + Sham
    The intervention will consist in a sham version of the StrokeWear system and usual clinical care under the direction of a clinician. The sham version of the StrokeWear system will include sensing and recording technology to detect GDMs. However, study participants will not receive feedback from the system regarding the GDM counts.

Primary outcome measures

  • Change in Motor Activity Log-Amount of Use [Time frame: Change from baseline Motor Activity Log-Amount of Use score at 6 months]
  • Change in Fugl-Meyer Upper-Extremity [Time frame: Change from baseline Fugl-Meyer Upper-Extremity score at 6 months]
  • Change in Upper-Extremity Activity Counts [Time frame: Change from baseline Upper-Extremity Activity Counts score at 6 months]
Secondary outcome measures (6)
  • Change in Motor Activity Log-Quality of Use [Time frame: Change from baseline Motor Activity Log-Quality of Use score at 6 months]
  • Change in Wolf-Motor Function Test - Time subscale [Time frame: Change from baseline Wolf-Motor Function Test - Time subscale score at 6 months]
  • Change in Wolf-Motor Function Test - Functional ability subscale [Time frame: Change from baseline Wolf-Motor Function Test - Functional ability subscale score at 6 months]
  • Change in Stroke Impact Scale (SIS) [Time frame: Change from baseline Stroke Impact Scale (SIS) score at 6 months]
  • Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale [Time frame: Change from baseline Stroke Self-Efficacy Questionnaire (SSEQ) - Activity subscale score at 6 months]
  • Change in Stroke Self-Efficacy Questionnaire (SSEQ) - Self-management subscale [Time frame: Change from baseline Self-Efficacy Questionnaire (SSEQ) - Self-management subscale score at 6 months]

Eligibility criteria

Inclusion criteria

  • Male or female, 18-85 years of age at the time of enrollment
  • Anterior circulation ischemic stroke at least 1 month and no more than 6 months prior to study enrollment;
  • Unilateral upper extremity hemiparesis as characterized by initial scores on upper limb subtest of the Fugl-Meyer Assessment (FMA-UE) between 20 and 45;
  • Intact cognitive function to understand the study procedures and goal setting (MMSE score above 23 and able to follow 3step command) ;
  • Owning a smartphone (iOS or Android) and being familiar and comfortable with and owning a tablet or smartphone
  • SAFE score equal or greater than 5

Exclusion criteria

  • Severe spasticity (defined as a Modified Ashworth scale score of 3 or more) that would prevent safe performance of UE tasks;
  • Visual impairments as assessed by the NIH Stroke Scale Visual Field subscale (only subjects with no visual loss will participate in the study); or hemispatial neglect that would impair the subject ability to see the feedback on the app screen (as assessed with the Mesulum cancellation test);
  • Individuals with open wounds or recent fracture (less than 3 months) in the upper extremity, fragile skin or active infection;
  • Upper-extremity orthopedic injuries or severe pain resulting in movement limitations;
  • Diagnosis of other neurological disease; (i.e., Parkinson's disease, multiple sclerosis, ...);
  • Severe proprioceptive deficits that impair the ability to process the vibration feedback, as assessed by physical examination during screening;
  • Not understanding spoken or written English;
  • Contralateral motor deficits as assessed by clinical examination;
  • Brainstem and cerebellar stroke.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Spaulding Rehabilitation Hospital — Boston

Identifiers

NCT: NCT06797154 · 2024P003622 · R44HD084035

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗